Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P08686: Variant p.Arg357Gln

Steroid 21-hydroxylase
Gene: CYP21A2
Feedback?
Variant information Variant position: help 357 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Arginine (R) to Glutamine (Q) at position 357 (R357Q, p.Arg357Gln). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to medium size and polar (Q) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In AH3; simple virilizing form; mild; 0.65% activity. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 357 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 495 The length of the canonical sequence.
Location on the sequence: help YKDRARLPLLNATIAEVLRL R PVVPLALPHRTTRPSSISGY The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         YKDRARLPLLNATIAEVLRLRPVVPLALPHRTTRPSSISGY

                              YRDPTRLPLLSATVAEVLRLRPVVPLALPHCTTRPSSISGY

Mouse                         YRNRMQLPLLMATIAEVLRLRPVVPLALPHRATRASSISGY

Rat                           YKNRMQLPLLMATIAEVLRLRPVVPMALPHRATKASSISGY

Pig                           YKDRARLPLLNATIAEVLRLRPVVPLALPHRATRPSSIFGY

Bovine                        YKDRARLPLLNATIAEVLRLRPVVPLALPHRTTRPSSIFGY

Cat                           LKDPSRLPLLTATIAEVLRLRPVVPLALPHRTTRHSSILGY
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 495 Steroid 21-hydroxylase
Binding site 366 – 366



Literature citations
A cluster of missense mutations at Arg356 of human steroid 21-hydroxylase may impair redox partner interaction.
Lajic S.; Levo A.; Nikoshkov A.; Lundberg Y.; Partanen J.; Wedell A.;
Hum. Genet. 99:704-709(1997)
Cited for: VARIANTS AH3 PRO-357 AND GLN-357; Identification of CYP21 mutations, one novel, by single strand conformational polymorphism (SSCP) analysis.
Witchel S.F.; Smith R.; Suda-Hartman M.;
Hum. Mutat. 13:172-172(1999)
Cited for: VARIANTS AH3 TYR-170; LEU-282 AND GLN-357; Detection and assignment of CYP21 mutations using peptide mass signature genotyping.
Zeng X.; Witchel S.F.; Dobrowolski S.F.; Moulder P.V.; Jarvik J.W.; Telmer C.A.;
Mol. Genet. Metab. 82:38-47(2004)
Cited for: VARIANTS AH3 LEU-31; ASN-173; ASN-237; GLU-238; LYS-240; LEU-282; SER-292; GLN-357; TRP-357; TYR-366; SER-454; LEU-480 AND PRO-484;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.